Disease management programs for glaucoma: Has the vision become a reality?

Disease Management and Health Outcomes

Volumn 15, Issue 4, 2007, Pages 199-205

  Goldberg, Lawrence D ^a,b  

^a MD and Associates   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAXOLOL;

AGEISM; BLINDNESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; EYE EXAMINATION; FOLLOW UP; GLAUCOMA; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; INTRAOCULAR PRESSURE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SCREENING; TRABECULOPLASTY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 34548369624     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200715040-00001     Document Type: Review

References (41)

1. Quigley HA, Vitale S. Models of glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997; 38: 83-91
2. Hattenhauer MG, Johnson DH, Ing HH, et al. The probability of blindness from open-angle glaucoma. Ophthalmology 1998; 105: 2099-104
3. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996 May; 80 (5): 389-93
4. Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998 May; 116 (5): 653-8
5. Khandekar R, Mohammed AJ, Raisi AA. Prevalence and causes of blindness and low vision: before and five years after 'VISION 2020' initiatives in Oman. A review. Ophthalmic Epidemiol 2007 Jan-Feb; 14 (1): 9-15
6. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006 Mar; 90 (3): 262-7
7. American Academy of Ophthalmology. Primary open-angle glaucoma, preferred practice pattern. San Francisco (CA): American Academy of Ophthalmology, 2005 [online]. Available from URL: http://www.aao.org/ppp [Accessed 2006 Apr 26]
8. Wilson MR, Kosoko O, Cowan Jr CL, et al. Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. Am J Ophthalmol 2002; 134: 399-405
9. Schappert SM. Office visits for glaucoma: United States, 1991-1992. Adv Data 1995; 262: 1-14
10. National Advisory Council, National Institutes of Health, National Eye Institute. Vision research: a national plan 1999-2003. Glaucoma Panel report [online]. Available from URL: http://www.nei.nih.gov/resources/strategicplans/ neiplan/frm_glaucoma.asp [Accessed 2006 Jun 5]
11. Weih LM, Nanjan M, McCarty CA, et al. Prevalence and predictors of open-angle glaucoma: results from the visual impairment project. Ophthalmology 2001 Nov; 108 (11): 1966-72
12. Hitzl W, Bunce C, Reitsamer HA, et al. The projected increase in glaucoma due to the aging population in Austria from 2001 to 2031: results based on data of the Salzburg-Moorfields Collaborative Glaucoma Study. Eur J Ophthalmol 2007 Jan-Feb; 17 (1): 45-52
13. Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 2006; 124: 12-9
14. Kerrigan-Baumrind LA, Quigley HA, Pease ME, et al. Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. Invest Ophthalmol Vis Sci 2000; 41: 741-8
15. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13
16. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-79
17. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943-53
18. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126: 487-97
19. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-40
20. American Academy of Ophthalmology. Primary open-angle glaucoma suspect, preferred practice pattern. San Francisco (CA): American Academy of Ophthalmology, 2005 [online]. Available from URL: http://www.aao.org/ppp [Accessed 2006 Nov 5]
21. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998 Oct; 126 (4): 498-505
22. Anderson DR, Normal Tension Glaucoma Study. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol 2003 Apr; 14 (2): 86-90
23. Thomas R, Sekhar GC, Kumar RS. Glaucoma management in developing countries: medical, laser, and surgical options for glaucoma management in countries with limited resources. Curr Opin Ophthalmol 2004 Apr; 15 (2): 127-31
24. Holmstrom S, Buchholz P, Walt J, et al. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries. Curr Med Res Opin 2006 May; 22 (5): 897-905
25. Fremont AM, Lee PP, Mangione CM, et al. Patterns of care for open-angle glaucoma in managed care. Arch Ophthalmol 2003; 121: 778-83
26. Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol 2006; 17: 190-5
27. Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol 2005; 89: 1245-9
28. Iskedjian M, Walker J, Vicente C, et al. Cost of glaucoma in Canada: analyses based on visual field and physician's assessment. J Glaucoma 2003; 12: 456-62
29. Goldberg LD, Walt JG, Lee JT. Comparing treatment costs associated with screening for glaucoma vs not screening: evaluating the economic impact of the new HEDIS measure [abstract]. J Managed Care Pharm 2004; 10: 463
30. Hitzl W, Ortner C, Hornykewycz K, et al. Resource use and costs for a glaucoma screening program in Austria: an 8-year review. A cost-consequence analysis based on the Salzburg-Moorfields Collaborative Glaucoma Study. Eur J Ophthalmol 2006; 16 (1): 92-9
31. South East Asia Glaucoma Interest Group (SEAGIG). Asia Pacific glaucoma guidelines. 2003-2004 [online]. Available from URL: http://seagig.org/images/ stories/downloads/APGGuidelinesNMview.pdf [Accessed 2006 Nov 5]
32. European Glaucoma Society. Definitions and guidelines for glaucoma, 2003 [on-line]. Available from URL: http://www.eugs.org/ebook.asp [Accessed 2006 Nov 5]
33. Tuulonen A, Airaksinen PJ, Erola E, et al. The Finnish evidence-based guideline for open-angle glaucoma. Acta Ophthalmol Scand 2003; 81: 3-18
34. Damji KF, Behki R, Wang L, et al. Canadian perspectives in glaucoma management: setting target intraocular pressure range. Can J Ophthalmol 2003; 38: 189-97
35. National Library for Health. National Screening Committee policy: glaucoma screening [online]. Available from URL: http://www.library.nhs.uk/ screening/ViewResource.aspx?.resID=61003 [Accessed 2007 Feb 5]
36. European Expert Symposium on Management of Glaucoma; 2003 May 17-18; Saint Tropez
37. Quigley HA, Jampel HD. How are glaucoma patients identified? J Glaucoma 2003; 12: 451-5
38. US Department of Health and Human Services, Centers for Medicare & Medicaid Services. Glaucoma screening [online]. Available from URL: http://www.cms.hhs.gov/GlaucomaScreening/ [Accessed 2007 Feb 5]
39. The state of health care quality: 2005. Washington, DC: National Committee for Quality Assurance, 2005 [online]. Available from URL: http://web.ncqa.org/tabid/447/Default.aspx [Accessed 2006 Nov 5]
40. Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics 2006; 24: 251-64
41. Levin LA. Neuroprotection and regeneration in glaucoma. Ophthalmol Clin North Am 2005; 18: 585-96